Mandate

Vinge is advising Xspray Pharma in connection with its rights issue of units

Through the rights issue of units, Xspray is expected to receive approximately SEK 300 million, with two warrant series approximately amounting together up to an additional SEK 300 million upon full exercise.

Xspray Pharma AB (publ) is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment. The company's goal is to become a leader in the development of improved PKIs for cancer treatment. Xspray’s shares are listed on Nasdaq Stockholm.

Vinge’s team primarily consisted of Dain Hård NevonenLinnéa Sellström and Adrian Filipovic.

 

Related

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024

Vinge advises Sobro in connection with investment in Clinton Marine Survey

Clinton Marine Survey has chosen to broaden its ownership with Sobro as a new partner and majority shareholder. All existing owners remain as significant shareholders. Clinton Marine Survey offers high quality hydrographic and geological surveys for navigation, dredging operations, mapping, marine construction and more.
April 09, 2024

Vinge has advised Helix Kapital in connection with the fund formation of Helix Kapital Fund III

Vinge has advised Helix Kapital in the establishment of Helix Kapital’s third fund, Helix Kapital Fund III. The fund closed successfully with commitments of approximately SEK 1.5 billion from an international investor base consisting of a number of leading financial institutions. The investor interest in the fund raising was very strong, and the fund was significantly oversubscribed.
April 05, 2024